Sumi  Shrishrimal net worth and biography

Sumi Shrishrimal Biography and Net Worth

EVP, Chief Risk Officer of iRhythm Technologies

Sumi Shrishrimal has served as our Chief Risk Officer since May 2022. From May 2018 to May 2022, Ms. Shrishrimal held various positions with DexCom, Inc., most recently as Chief Risk Officer. From March 2016 to May 2018, Ms. Shrishrimal served as Vice President, Internal Audit at NuVasive, Inc., and previously served as their Senior Director, Internal Audit, from November 2014 to February 2016. From December 2003 to October 2014, Ms. Shrishrimal served in various roles at Corinthian Colleges, most recently as Vice President, Internal Audit.

Ms. Shrishrimal holds a B.A. in Accounting and Information Systems from University of Mumbai in India.

What is Sumi Shrishrimal's net worth?

The estimated net worth of Sumi Shrishrimal is at least $1.72 million as of June 3rd, 2024. Ms. Shrishrimal owns 23,298 shares of iRhythm Technologies stock worth more than $1,717,995 as of November 21st. This net worth estimate does not reflect any other assets that Ms. Shrishrimal may own. Learn More about Sumi Shrishrimal's net worth.

How old is Sumi Shrishrimal?

Ms. Shrishrimal is currently 45 years old. There are 5 older executives and no younger executives at iRhythm Technologies. The oldest executive at iRhythm Technologies is Mr. Marc Rosenbaum, Senior VP of Finance & Chief Accounting Officer, who is 52 years old. Learn More on Sumi Shrishrimal's age.

How do I contact Sumi Shrishrimal?

The corporate mailing address for Ms. Shrishrimal and other iRhythm Technologies executives is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. iRhythm Technologies can also be reached via phone at (415) 632-5700 and via email at [email protected]. Learn More on Sumi Shrishrimal's contact information.

Has Sumi Shrishrimal been buying or selling shares of iRhythm Technologies?

Sumi Shrishrimal has not been actively trading shares of iRhythm Technologies in the last ninety days. Most recently, Sumi Shrishrimal sold 1,131 shares of the business's stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $88.91, for a transaction totalling $100,557.21. Following the completion of the sale, the executive vice president now directly owns 23,298 shares of the company's stock, valued at $2,071,425.18. Learn More on Sumi Shrishrimal's trading history.

Who are iRhythm Technologies' active insiders?

iRhythm Technologies' insider roster includes C. Bairey Merz (Director), Quentin Blackford (CEO), Mark Day (EVP), Douglas Devine (CFO), Patrick Murphy (EVP), Chad Patterson (Chief Commercial Officer), Sumi Shrishrimal (EVP, Chief Risk Officer), Mervin Smith (EVP of Business Operations), Minang Turakhia (Chief Medical Officer, Chief Scientific Officer and EVP, Product Innovation), David Vort (EVP), and Daniel Wilson (EVP). Learn More on iRhythm Technologies' active insiders.

Are insiders buying or selling shares of iRhythm Technologies?

In the last year, iRhythm Technologies insiders bought shares 2 times. They purchased a total of 6,944 shares worth more than $521,860.64. In the last year, insiders at the sold shares 12 times. They sold a total of 66,532 shares worth more than $6,937,400.34. The most recent insider tranaction occured on November, 4th when Director Abhijit Y Talwalkar bought 6,664 shares worth more than $500,866.24. Insiders at iRhythm Technologies own 0.7% of the company. Learn More about insider trades at iRhythm Technologies.

Information on this page was last updated on 11/4/2024.

Sumi Shrishrimal Insider Trading History at iRhythm Technologies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/3/2024Sell1,131$88.91$100,557.2123,298View SEC Filing Icon  
See Full Table

Sumi Shrishrimal Buying and Selling Activity at iRhythm Technologies

This chart shows Sumi Shrishrimal's buying and selling at iRhythm Technologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

iRhythm Technologies Company Overview

iRhythm Technologies logo
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $73.74
Low: $72.36
High: $75.15

50 Day Range

MA: $72.82
Low: $57.07
High: $89.50

2 Week Range

Now: $73.74
Low: $55.92
High: $124.11

Volume

558,042 shs

Average Volume

613,413 shs

Market Capitalization

$2.31 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23